QuartrQuartr

PEG: Loss narrowed, clinical milestones advanced, and 2026 guidance targets first revenue

Thời gian đọc: dưới 1 phút

Net loss narrowed significantly in 2025 due to lower R&D spend and cost discipline. Clinical progress included regulatory approval for RNX-011 Phase 2 and advanced partner talks for RNX-051. 2026 guidance anticipates first revenues and continued clinical milestones.

Original document: Pharma Equity Group A/S Class A [PEG] Slides Release — Mar. 25 2026

Thông báo miễn trừ trách nhiệm